347 related articles for article (PubMed ID: 16151977)
1. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
2. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
3. Insulin glulisine: a faster onset of action compared with insulin lispro.
Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
[TBL] [Abstract][Full Text] [Related]
4. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
Cernea S; Kidron M; Wohlgelernter J; Raz I
Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique.
Becker RH; Frick AD; Burger F; Scholtz H; Potgieter JH
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):292-7. PubMed ID: 15926116
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
[TBL] [Abstract][Full Text] [Related]
7. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
10. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
11. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Rave K; Klein O; Frick AD; Becker RH
Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
[TBL] [Abstract][Full Text] [Related]
12. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
Arnolds S; Rave K; Hövelmann U; Fischer A; Sert-Langeron C; Heise T
Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):662-4. PubMed ID: 20429049
[TBL] [Abstract][Full Text] [Related]
13. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
[TBL] [Abstract][Full Text] [Related]
14. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
Umpierrez GE; Latif K; Stoever J; Cuervo R; Park L; Freire AX; E Kitabchi A
Am J Med; 2004 Sep; 117(5):291-6. PubMed ID: 15336577
[TBL] [Abstract][Full Text] [Related]
16. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
[TBL] [Abstract][Full Text] [Related]
17. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro.
Chao M; Wang W; Zhang Y; Lu X; Meng J; Ning G
Endocrine; 2010 Aug; 38(1):48-52. PubMed ID: 20960101
[TBL] [Abstract][Full Text] [Related]
19. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
20. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
